The combination of erlotinib and crizotinib (a c-Met pathway inhibitor) diminished importantly tumor volume as well as the phosphorylation of EGFRvIII, Met, AKT, and MAPK in primary human GBM subcutaneous xenografts. Here, MET is linked to neoplasm.